Australia Markets closed

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.4700-0.1100 (-3.07%)
At close: 04:00PM EST
3.6400 +0.17 (+4.90%)
After hours: 04:22PM EST
Full screen
Trade prices are not sourced from all markets
Previous close3.5800
Open3.6000
Bid3.3500 x 3000
Ask3.6400 x 1000
Day's range3.4100 - 3.6800
52-week range3.4100 - 30.1400
Volume558,528
Avg. volume803,254
Market cap132.625M
Beta (5Y monthly)2.17
PE ratio (TTM)N/A
EPS (TTM)-2.4640
Earnings date09 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.90
  • Zacks

    Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks

    TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • GlobeNewswire

    TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

    CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities. “We are

  • GlobeNewswire

    TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones

    - Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x108 cells/m2- Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022- Initial data from TC-510 Phase 1/2 trial anticipated in 2H 2022- Selection of lead allogeneic TRuC-T cell candidate anticipated in 2022- TCR2 to present an update on Company progress at the J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30AM E.T. CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIR